by | Apr 26, 2024 | Publications
Discov Med. 2024 Apr;36(183):721-729. doi: 10.24976/Discov.Med.202436183.68. ABSTRACT BACKGROUND: Multiple myeloma (MM) is a malignant disorder of plasma cells in the bone marrow. MM causes the clonal proliferation of terminally differentiated plasma cells and the...
by | Apr 26, 2024 | Publications
Biochem Med (Zagreb). 2024 Jun 15;34(2):020801. doi: 10.11613/BM.2024.020801. Epub 2024 Apr 15. ABSTRACT Less than 2% of all symptomatic multiple myeloma (MM) has immunoglobulin D (IgD) as monoclonal protein. Biclonal gammopathy is much rarer. At the time of...
by | Apr 26, 2024 | Publications
Front Oncol. 2024 Apr 11;14:1291055. doi: 10.3389/fonc.2024.1291055. eCollection 2024. ABSTRACT BACKGROUND: Multiple myeloma is diagnosed in 5,800 people in the United Kingdom (UK) each year with up to 64% having vertebral compression fractures at the time of...
by | Apr 25, 2024 | Publications
Blood. 2024 Apr 24:blood.2023022823. doi: 10.1182/blood.2023022823. Online ahead of print. ABSTRACT Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma...
by | Apr 25, 2024 | Publications
JMIR Res Protoc. 2024 Apr 24;13:e49861. doi: 10.2196/49861. ABSTRACT BACKGROUND: Multiple myeloma (MM) is the second-most common cancer among hematological malignancies. Patients with active disease may experience several comorbidities, including renal insufficiency...
by | Apr 25, 2024 | Publications
Acta Haematol. 2024 Apr 24. doi: 10.1159/000539066. Online ahead of print. ABSTRACT INTRODUCTION: Some treatments are associated with cytomegalovirus (CMV) reactivation (CMVRA) in patients with multiple myeloma (MM). However, no reports exist on the association...